Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors

Stefano Fogli, Marzia Del Re, Giuseppe Curigliano, Ron H. van Schaik, Patrizio Lancellotti, Romano Danesi

Research output: Contribution to journalReview articlepeer-review


CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors. Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may be useful in decision-making processes and represent an important step towards treatment personalization. The present review is aimed at describing the potential DDIs that might occur in breast cancer patients receiving CDK4/6 inhibitors based on direct evidence from the literature and mechanistic considerations tailored on specific class of drugs used in combination.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalCancer Treatment Reviews
Publication statusPublished - Mar 2019


  • Breast cancer
  • CDK4/6 inhibitors
  • Drug-drug interaction
  • Pharmacodynamics
  • Pharmacokinetics
  • Treatment personalization

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors'. Together they form a unique fingerprint.

Cite this